Mr. Lapidus will help advance Lucid’s EsoGuard and EsoCheck commercialization efforts.
Lucid is creating a series of noninvasive diagnostic tests to identify esophageal cancer and Barrett’s esophagus.
Mr. Lapidus said: “Lucid Diagnostics’ EsoGuard and EsoCheck technologies have the potential to be game changers in the diagnosis of conditions along the spectrum from Barrett’s Esophagus to esophageal cancer, which is a growing scourge. … I look forward to working with them as they accelerate commercialization, embark on important IVD clinical trials and explore capital market strategies.”
More articles on ASCs:
The ‘new normal’ for ASCs: 16 admins on how the pandemic will change the field forever
Dr. Thomas Vikoren: Same-day TJR ‘made all the more important’ by COVID-19
Indiana orthopedic practice with surgery center to open
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
